On June 24, 2019 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, reported that it will be giving a talk and presenting a poster at the Cell Engager Therapeutics Summit in Boston, US, held from 25-27 June 2019 (Press release, Crescendo Biologics, JUN 24, 2019, View Source [SID1234537222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Crescendo’s Chief Medical Officer, Dr Pavel Pisa’s, talk entitled ‘Humabody VH as T-cell Enhancing Therapeutics for Immuno-Oncology’ is focused on the beneficial attributes and planned clinical application of CB307. CB307 is a novel CD137-PSMA-HSA tri-specific that enables tumour selective T-cell activation, while minimising systemic toxicity.

‘Humabody VH as T-cell Enhancing Therapeutics for Immuno-Oncology’ – talk by Dr Pavel Pisa 26 June, 12:00pm.

Crescendo will also present a poster at the Summit, entitled ‘CB307: A novel T-cell costimulatory Humabody VH therapeutic for PSMA-positive tumours’. The poster will show preclinical data obtained on Crescendo’s lead programme, CB307. The poster will illustrate the generation, functional characterisation and potential therapeutic application of CB307 in PSMA-positive solid tumours.